BridgeMD
New treatment option for Multiple Sclerosis
Official title Cognitive-motor Telerehabilitation in MS
ClinicalTrials.gov ID: NCT05355389
What this study is testing
- What it's testing
- The primary goal of this project is providing evidence that a home-based combined cognitive-motor training program improves cognition in persons with multiple sclerosis (MS), compared to single cognitive and motor rehabilitation. Secondary goals are to assess the effects on walking performance and to identify the mechanisms of improvement and predictors of treatment response.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Clinically definite multiple sclerosis (revised McDonald criteria 2017)
- Expanded Disability Status Scale (EDSS) below 6.0
- Digit span backwards z-score between [-3 and -0.5] standard deviations below the median of the normative values
- Age between 18 and 65
- Able to safely perform motor rehabilitation in the home situation (assessed by rehabilitation physician and/or occupational or physiotherapist)
You likely can't join if
- Cognitive rehabilitation within six months before inclusion
- Inpatient multidisciplinary rehabilitation program within three months before inclusion or planned inpatient program during trial
- Start of or switch in immunomodulator treatment within three months before inclusion
- Less than one month post-exacerbation
- Major psychiatric or medical disorder that could influence cognitive functions
- Combined vision with optimal correction below 0.6 on Snellen Visual Acuity Test
See the full eligibility criteria
- Clinically definite multiple sclerosis (revised McDonald criteria 2017)
- Expanded Disability Status Scale (EDSS) below 6.0
- Digit span backwards z-score between [-3 and -0.5] standard deviations below the median of the normative values
- Age between 18 and 65
- Able to safely perform motor rehabilitation in the home situation (assessed by rehabilitation physician and/or occupational or physiotherapist)
- Cognitive rehabilitation within six months before inclusion
- Inpatient multidisciplinary rehabilitation program within three months before inclusion or planned inpatient program during trial
- Start of or switch in immunomodulator treatment within three months before inclusion
- Less than one month post-exacerbation
- Major psychiatric or medical disorder that could influence cognitive functions
- Combined vision with optimal correction below 0.6 on Snellen Visual Acuity Test
- Unable or unwilling to undergo EEG or MRI
- Refusing informed consent
The study team makes the final eligibility decision.
Where it's taking place
- Brussels, Belgium
- Melsbroek, Belgium
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Brussels, Belgium; Melsbroek, Belgium. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.